A quiet algorithmic coup recently reshaped American medicine. The American College of Cardiology and the American Heart Association released their updated dyslipidemia guidelines. By retiring older risk calculators in favor of the new Predicting Risk of Cardiovascular Disease EVENTS, or PREVENTS, equations, these centralized medical bodies expanded the age range for primary cardiovascular prevention up to age 79. In one stroke, this bureaucratic shift made an estimated 21 million to 25 million more Americans newly eligible for cholesterol-lowering therapy.

While medical boards use these sweeping, top-down age brackets to dictate broad prescribing habits, they ignore a critical clinical truth. True medicine is inherently individualized. The question of whether an older patient should start, continue, or stop taking a statin cannot be answered by an institutional calendar date. Unfortunately, federal health regulations and insurance frameworks increasingly reward cookie-cutter compliance while actively restricting access to the precise, advanced therapies that can alter a patient’s life.